Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

230 Press Releases
DateTitleCompany
05 Feb 16 SPIRIVA® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents Boehringer Ingelheim,
Published by
PharmiWeb.com
27 Jan 16 Boehringer Ingelheim’s Giotrif® (afatinib) demonstrated superiority to gefitinib in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer Boehringer Ingelheim,
Published by
Business Wire
27 Jan 16 Boehringer Ingelheim is Pleased to Welcome Green Light from the National Institute for Health and Care Excellence (NICE) for Its Medicine for Rare Lung Disease. Boehringer Ingelheim,
Published by
Business Wire
27 Jan 16 Idiopathic Pulmonary Fibrosis (IPF): OFEV?® (nintedanib) is recommended for use within the NHS by the National Institute for Health and Care Excellence (NICE) Boehringer Ingelheim,
Published by
Business Wire
12 Jan 16 Type 2 diabetes: All Wales Medicines Strategy Group recommends Jardiance®? (empagliflozin) as an option for patients with type 2 diabetes in Wales Boehringer Ingelheim,
Published by
Business Wire
21 Dec 15 Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer Boehringer Ingelheim,
Published by
Business Wire
30 Nov 15 Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) Boehringer Ingelheim,
Published by
PharmiWeb.com
30 Nov 15 Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment Boehringer Ingelheim,
Published by
Business Wire
26 Nov 15 Praxbind® ? (idarucizumab) licensed in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) Boehringer Ingelheim,
Published by
Business Wire
23 Nov 15 FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Prophylaxis of Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) after Hip Replacement Surgery Boehringer Ingelheim,
Published by
PharmiWeb.com
18 Nov 15 Boehringer Ingelheim Makes Twitter #COUGH for World COPD Day Boehringer Ingelheim,
Published by
Business Wire
17 Nov 15 NICE Endorsed Tool Launched to Support Patients and Doctors in Shared Decision-Making. Boehringer Ingelheim,
Published by
Business Wire
16 Nov 15 Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab Boehringer Ingelheim,
Published by
PharmiWeb.com
16 Nov 15 Boehringer Ingelheim Presents New Praxbind® (idarucizumab) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran Boehringer Ingelheim,
Published by
PharmiWeb.com
16 Nov 15 Real-World Analysis of More Than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) in Routine Clinical Care Boehringer Ingelheim,
Published by
PharmiWeb.com
30 Oct 15 Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab Boehringer Ingelheim,
Published by
PharmiWeb.com
28 Oct 15 Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab Boehringer Ingelheim,
Published by
Business Wire
19 Oct 15 FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) Boehringer Ingelheim,
Published by
Business Wire
27 Sep 15 ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status Boehringer Ingelheim,
Published by
Business Wire
27 Sep 15 VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone Boehringer Ingelheim,
Published by
Business Wire
25 Sep 15 Extending overall survival is less important than quality of life and disease stability for the majority of physicians treating patients with advanced lung cancer following first line-chemotherapy Boehringer Ingelheim,
Published by
Business Wire
25 Sep 15 Extending overall survival is less important than quality of life and disease stability for the majority of physicians treating patients with advanced lung cancer following first-line chemotherapy Boehringer Ingelheim,
Published by
Business Wire
25 Sep 15 CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) Boehringer Ingelheim,
Published by
Business Wire
28 Sep 15 COPD: New Data Support Role of Spiolto® Respimat® as 1st-line Maintenance Therapy and Show Superiority over LABA/ICS Boehringer Ingelheim,
Published by
Business Wire
17 Sep 15 New data demonstrates Jardiance®? (empagliflozin) showed a significant reduction in cardiovascular risk in diabetes patients in a dedicated outcome trial Boehringer Ingelheim,
Published by
Business Wire
21 Sep 15 ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments Boehringer Ingelheim,
Published by
Business Wire
21 Sep 15 Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD Boehringer Ingelheim,
Published by
Business Wire
08 Oct 15 Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study Boehringer Ingelheim,
Published by
Business Wire
08 Oct 15 Delayed IPF diagnosis negatively impacts patients by delaying treatment according to global survey of pulmonologists1 Boehringer Ingelheim,
Published by
PharmiWeb.com
08 Oct 15 Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study Boehringer Ingelheim,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.